Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Sponsor
Fudan University
Study ID
NCT07117877
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Ovarian Cancer (OvCa)
  • Platinum Refractory Epithelial Ovarian Cancer
  • Platinum Resistant Ovarian Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Etoposide Capsules — DRUG
    50 mg(25mg/pill, 2 pills at a time) orally, qd, days 1 to 14, per cycle
  • Bevacizumab — DRUG
    7.5mg/kg, i.v, q3w
  • Iparomlimab and Tuvonralimab (QL1706) — DRUG
    5mg/kg, i.v., q3w

Study Details

This study is a Prospective, Single-arm, Phase II clinical trial. The purpose of this study is to find out if taking Etoposide Capsules combined With Bevacizumab and Iparomlimab and Tuvonralimab is safe and works well for people with platinum-resistant or platinum refractory ovarian cancer . Researchers will look at the Progression-Free Survival, Objective Response Rate, Overall Survival, safety, and any side effects.

Key Dates

First listed
Aug 12, 2025
Start date
Sep 15, 2025
Status verified
Aug 2025
Primary completion
Aug 31, 2026
Completion
Aug 31, 2027

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Etoposide+Bevacizumab+Iparomlimab and Tuvonralimab
    Participants will receive Etoposide Capsules, Bevacizumab and Iparomlimab and Tuvonralimab in combination. 21 days as a cycle.

Primary Outcome Measure

PFS [ Time Frame: approximately 2 years ]

Central Contacts

Related Studies